NCT07010198View on ClinicalTrials.gov

Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City

RecruitingOBSERVATIONAL
Enrollment

4,500

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Hepatocellular Cancer (HCC)
Interventions
DIAGNOSTIC_TEST

Quantitative HBeAg Testing

Quantitative HBeAg Testing in Population-Based Primary Screening

BIOLOGICAL

Measurement Indicators Required for Risk Scoring in HCC Screening Strategies

REACH-B: Age, Sex, HBeAg status, ALT levels, and HBV DNA load; AGED: Age, Sex, HBeAg status, HBV DNA load; aMAP: Age, Sex, Albumin, Total Bilirubin, Platelet Count; aMAP 3.0: Age, Sex, Albumin, Total Bilirubin, Platelet Count, AFP and PIVKA-II.

BIOLOGICAL

Follow-Up Monitoring Parameters

AFP, Liver Ultrasound

Trial Locations (1)

528403

RECRUITING

Zhongshan People's Hospital, Zhongshan

All Listed Sponsors
lead

Zhongshan People's Hospital, Guangdong, China

OTHER